Platelet volume as a parameter for platelet activation in patients with endometrial cancer

Oge T., YALÇIN Ö. T., Ozalp S. S., Isikci T.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY, cilt.33, sa.3, ss.301-304, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.3109/01443615.2012.758089
  • Dergi Adı: JOURNAL OF OBSTETRICS AND GYNAECOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.301-304
  • Anahtar Kelimeler: Endometrial adenocarcinoma, mean platelet volume, MPV, platelet, platelet activation, PROGNOSTIC-SIGNIFICANCE, RADICAL HYSTERECTOMY, OVARIAN-CARCINOMA, GROWTH-FACTOR, THROMBOCYTOSIS, SIZE, HEMOGLOBIN, COUNT, ANGIOGENESIS, RECEPTOR
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

The objective of this study was to use mean platelet volume (MPV) as a measure of platelet activation in patients with endometrial adenocarcinoma and healthy controls. There was a total of 310 patients with endometrial adenocarcinoma retrospectively evaluated and 250 healthy controls. Preoperative haemoglobin, platelet counts and mean platelet volume were evaluated and statistical tests were conducted to determine the differences among early and advanced disease groups and controls. Median haemoglobin (13.0 vs 13.3 g/dl) and platelet count (282,000 vs 280,000/mu l) values were similar in patients with endometrial adenocarcinoma and healthy controls (p > 0.05). Subjects with endometrial cancer exhibited slightly higher MPV than the control group (8.4 fl vs 8.2 fl) (p = 0.048). In patients with advanced-stage endometrial cancer, haemoglobin was significantly lower (p < 0.05) and MPV was significantly higher (p < 0.05) than in either patients with early-stage endometrial cancer or the control group. It was concluded that MPV was found to be a marker for predicting advanced-stage endometrial cancers.